Clariane's Stock Surpasses €4, Eyes Resistance at €4.10
The stock of the retirement home group is gaining ground this Tuesday, May 5, 2026, in a well-oriented Parisian market. At mid-session, Clariane's shares are at €4.07, up from €3.98 at the previous close. The CAC 40 is up 0.64% in the session, following the DAX (+0.76%).
Clariane has advanced 2.36% to €4.07 and is nearing its identified resistance at €4.10. The price has moved back above the 200-day moving average (€4.01) and remains well above the 50-day MA (€3.79). The movement continues the rebound observed after the announcement of the first quarter revenue on April 23. The RSI at 58 remains in a neutral zone, with no marked signs of bullish exhaustion. However, the stock is trading in the upper Bollinger Bands (upper boundary at €4.13), a position to monitor as the price tests the €4.10 zone.
Bond Refinancing and Financial Calendar in Focus
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At the end of April, the group launched an additional bond issue of €230 million at 6.875% maturing in 2031. This operation is in addition to the €500 million raised at the beginning of April, also aimed at refinancing existing debt. During the first quarter of 2026 announcement, the company confirmed its target for an average annual organic growth of about 5%. The quarterly revenue stood at €1,336 million, showing an organic growth of 4.9%. The next key date for shareholders is the annual general meeting, scheduled for Tuesday, May 12, 2026. Semi-annual results will follow on July 29.
SectorSanté · Etablissements de santé / EHPAD›Etablissements de santé
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1336M€
Guidance from the release
Avec une croissance organique de 4,9 %, le premier trimestre 2026 s’inscrit pleinement dans la dynamique.
Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m, en progression de +4,9%.
Risks mentioned
Impact des cessions intervenues en 2025 dans le cadre du plan de renforcement.
Risque lié aux conditions de marché futures.
Effets des défis réglementaires dans le secteur.
Opportunities identified
Lancement d'une obligation senior de €500m à échéance 2031.
Nouvelle dynamiqueprix/volume grâce aux mesures d’adaptation mises en place.
Engagement fort des collaborateurs pour atteindre les objectifs opérationnels.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
